FDA creates a device class for sinus-vibration stimulators that relieve congestion
A final order codifies 21 CFR 874.6010 for external mechanical stimulators that vibrate the sinus and nasal areas, placing the type in class II after a 2023 De Novo grant for Sound Health Systems' Sonu device.
The Food and Drug Administration has created a formal device category for a product that treats a stuffy nose by vibrating the face. A final order published in the Federal Register on 6 November 2026, effective the same day, places the "external mechanical stimulator for the relief of congestion" into class II with special controls and codifies it at 21 CFR 874.6010 [s1]. The agency identifies the device type as one "that delivers vibrations to the sinus and nasal areas to relieve congestion" [s1].
The order is administrative plumbing with a practical effect. It does not approve any single product so much as define the regulatory lane that this kind of product travels in, and in doing so it decides how much evidence a maker must show before selling one.
How this category came to exist
The category traces to a single device. On 16 June 2023, FDA received a request from Sound Health Systems, Inc. for "De Novo" classification of its Sonu device, and on 4 December 2023 the agency issued an order classifying the device into class II [s1]. The 6 November final order codifies that decision into the Code of Federal Regulations [s1].
De Novo is the pathway for a novel device of low to moderate risk that has no existing predicate to compare itself against. Without it, a device that is not high-risk but is genuinely new would be pushed by default into class III — the premarket approval tier meant for the highest-risk devices [s1]. A successful De Novo request both clears the specific device and, as here, can establish a new classification that later devices of the same type can use. FDA says the action will "enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens" [s1].
Once a type sits in class II, a later entrant can generally reach the market through a 510(k) premarket notification, showing substantial equivalence to a legally marketed device, rather than repeating a De Novo or mounting a premarket approval application. FDA notes it has not exempted this device type from 510(k), so premarket notification is still required [s1].
The risks the rule is built around
The special controls are written against specific hazards. FDA's order lists the risks to health for these stimulators as injury from mechanical overstimulation on the face — it names skin irritation or redness, pain, discomfort, headache, vertigo, hearing loss, and tinnitus — along with adverse tissue reaction, and "ineffective treatment leading to worsening congestion" [s1].
Against those, the regulation requires measures including non-clinical performance testing that verifies the device's mechanical stimulation parameters, electromagnetic compatibility, battery safety, and electrical safety testing, software verification, validation and hazard analysis, human factors testing, a biocompatibility evaluation, and labelling [s1]. A device has to meet these special controls to stay in class II and avoid being bumped back into class III [s1].
The last listed risk is the one a reader considering such a gadget should weigh: that it simply does not work, leaving congestion untreated. The order's answer to that is labelling, not a demonstrated cure — the classification sets the floor a product of this type must clear, and does not certify that any particular device relieves congestion well [s1].
What it means
For someone shopping for a drug-free congestion device, the change is quiet but real: products in this category are now regulated medical devices subject to named controls, not unclassified gadgets. It is not a verdict on effectiveness, and it does not name or endorse any brand beyond recording the Sonu device as the request that opened the category [s1]. What it fixes is the rulebook — the next such device now has a defined, lower-burden route to market, and a set of safety tests it cannot skip.
This article describes a federal device-classification action and is not medical advice.
Sources
- Medical Devices; Ear, Nose, and Throat Devices; Classification of the External Mechanical Stimulator for the Relief of Congestion (Final amendment; final order) — U.S. Food and Drug Administration / Federal Register , November 6, 2026
FDA creates a class II category for wearable bone-vibration devices
A final order published 5 November classifies wearable devices that apply targeted mechanical vibration to the skeleton to reduce loss of bone strength or density, setting the evidence such products must meet.
FDA classifies software that estimates a patient's odds of progressing to dementia
A final order published 5 November creates a class II category for prognostic software that weighs multiple clinical inputs to gauge the chance of progression from mild cognitive impairment — for adjunctive use only.
FDA sets a class II path for AI systems that help read Pap-test slides
A final order published 5 November creates a device category for digital cervical cytology imaging systems with AI, letting future versions clear through the 510(k) route instead of the strictest class III review.
FDA creates a class II category for at-home STI test kits read in the lab
A final order published 9 October classifies systems that let people collect their own specimens for non-viral STI testing as class II, moving them out of the automatic class III that demands premarket approval.